Combined Active Bone Marrow-Sparing Radiotherapy and Prophylactic PEG-rhG-CSF to Reduce Severe Neutropenia During Platinum-Doublet Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: A Phase II Trial.
Protecting bone marrow during cancer treatment helps patients complete chemotherapy and reduces severe infection risk.
This PubMed-indexed study examined bACKGROUND: Platinum-doublet concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC) is frequently complicated by severe neutropenia. The abstract reports cONCLUSIONS: The combination of ABMS radiotherapy and prophylactic PEG-rhG-CSF was associated with a grade ≥ 3 neutropenia rate of 13;0% and a chemotherapy completion rate of 85;2% during platinum-doublet CCRT for LACC.
What the study was
- Study design
- Clinical Trial
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer medicine
Why it surfaced
Conservative triage based on the PubMed abstract: clinical trial with direct watchlist relevance; score reflects metadata and abstract-level evidence only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.